Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition
Lei Gao(First Affiliated Hospital of Xi'an Jiaotong University), Liang Chen(Henan Medical University), Zhenzhen Fan(Jinan University), Xinyuan Tong(Chinese Academy of Sciences), Guang‐Biao Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Xin Hu(Emory University), Hsin‐Yi Huang(Center for Excellence in Molecular Cell Science), Mu‐Sheng Zeng(Sun Yat-sen University), Kun Wang(Chinese Academy of Sciences), Gong Zhang(Shanxi Medical University), Qing‐Yu He(Jinan University), Haiquan Chen(Fudan University Shanghai Cancer Center), Lei Yu(Beijing Tongren Hospital), Yong Hu(Jinan University), Wanting Liu(Jinan University), Hongdan Li(Jinzhou Medical University), Yahui Tian(Jinan University), Hongbin Ji(Westlake University), Shiyu Zhou(Institute of High Energy Physics), Qian Zhou(Jinan University), Qingsong Liu(Medical College of Wisconsin), Guandi Zeng(Jinan University)
Cited by 68
Related Papers
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
|Nature Medicine|2008|1.3k
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
|Cancer Cell|2006|451
Stem Cell Factor SOX2 Confers Ferroptosis Resistance in Lung Cancer via Upregulation of SLC7A11
|Cancer Research|2021|280